Back to search results

Study of ECC4703 and ECC0509 for MASH

This study is looking at new ways to treat Metabolic Dysfunction-associated Steatohepatitis (MASH), a type of liver disease. We are testing two medications, ECC4703 and ECC0509, alone and in combination, to see how well they reduce fat in the liver. You may be eligible if you are an adult between 18 and 75 years old with presumed MASH, based on a recent liver biopsy or a FibroScan® result showing liver scarring and metabolic risk factors. The main goal is to measure changes in liver fat using a special MRI scan after 12 weeks. The study is currently recruiting about 160 participants, but its exact status is unclear.

Study design
This is an interventional study comparing ECC4703, ECC0509, and their combination to a placebo. It plans to enroll 160 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 12, indicating a follow-up period of at least 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07288138

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Eccogene
~160 participants
Updated 2026-09-09 on ClinicalTrials.gov
What's tested:PlaceboECC4703ECC0509

At a glance

Recruiting sites
63 of 64 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relative Change from Baseline in Liver Fat Content by MRI-PDFF, Comparing ECC4703 Monotherapy Versus Placebo
Measured over Baseline and Week 12

Conditions

Metabolic Dysfunction-associated Steatohepatitis

Explore related trials

Nonalcoholic Steatohepatitis

NCT07288138

Where you'd take part

This study runs at 64 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Adobe Clinical Research, LLC

    Tucson, Arizonano site contact published

    Recruiting

  • Akron Gastro Research

    Akron, Ohiono site contact published

    Recruiting

  • ARcare Center for Clinical Research

    Little Rock, Arkansasno site contact published

    Recruiting

  • Arizona Liver Health

    Chandler, Arizonano site contact published

    Recruiting

  • Arizona Liver Health - Peoria

    Peoria, Arizonano site contact published

    Recruiting

  • Arizona Liver Health - Tucson

    Tucson, Arizonano site contact published

    Recruiting

  • Ark Clinical Research

    Long Beach, Californiano site contact published

    Recruiting

  • ARK Clinical Research - Fountain Valley

    Fountain Valley, Californiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Eccogene Clinical Trials · STUDY_DIRECTOR · Eccogene

Who to contact

Eccogene Clinical Trials
[email protected]
86-21-61053022
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Relative Change from Baseline in Liver Fat Content by MRI-PDFF, Comparing ECC4703 Monotherapy Versus PlaceboBaseline and Week 12